SEARCH:   Advanced

Blood, 15 October 2006, Vol. 108, No. 8, pp. 2604-2607. Prepublished online as a Blood First Edition Paper on June 15, 2006; DOI 10.1182/blood-2006-04-016527. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-04-016527v1 108/8/2604    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Coppens, M. Articles by Middeldorp, S. Search for Related Content PubMed PubMed Citation Articles by Coppens, M. Articles by Middeldorp, S. Related Collections Hemostasis, Thrombosis, and Vascular Biology Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation Michiel Coppens, Marlene H. van de Poel, Ivan Bank, Karly Hamulyak, Jan van der Meer, Nic J. Veeger, Martin H. Prins, Harry R. Buller, and Saskia Middeldorp From the Department of Vascular Medicine, Academic Medical Center, Amsterdam; the Department of Hematology, Division of Hemostasis, Thrombosis and Rheology, University Medical Center Groningen; the Department of Clinical Epidemiology and Medical Technology Assessment, Academic Hospital Maastricht; and the Department of Hematology, Academic Hospital Maastricht, The Netherlands. The prothrombin 20210A mutation has been associated with an increased risk for venous thromboembolism (VTE) and arterial cardiovascular disease. The risks for asymptomatic carriers of this mutation have thus far been studied only in case-control and retrospective cohort studies. Here we present the results of the first prospective observational study in asymptomatic first-degree family members of patients with either VTE or premature atherosclerosis and the prothrombin 20210A mutation. We included 464 individuals (236 carriers) with a total follow-up duration of 1816 years (943 years for the carriers). The annual incidence of a first VTE was 0.37% (95% CI, 0.08-1.08) for carriers and 0.12% (95% CI, 0.00-0.69) for noncarriers (HR, 3.1; 95% CI, 0.3-29.6). The annual incidence of a first arterial cardiovascular event was 0.56% (95% CI, 0.18-1.31) for carriers and 0.73% (95% CI, 0.27-1.58) for noncarriers (adjusted HR, 0.7; 95% CI, 0.2-2.5). We conclude that the absolute incidence of a first VTE or arterial cardiovascular event is low; therefore, the clinical implications of carriership of the prothrombin 20210A mutation are limited, and routinely testing all first-degree relatives of probands with this mutation does not appear to be justified. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020